Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Expressing the sense of the Congress with respect to the awareness, prevention, early detection, and effective treatment of viral hepatitis, and for other purposes.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.Con.Res.130, Expressing the sense of the Congress with respect to the awareness, prevention, early detection, and effective treatment of viral hepatitis, and for other purposes. Lobbied for awareness of Hepatitis B. H.R.2090, Food and Drug Administration Improvement Act of 2005. Lobbied to prevent provisions adverse to prescription drug approval process. H.R.3010, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2006, Lobbied for increased funding for AIDS Drug Assistance Program. H.R.328, Pharmaceutical Market Access Act of 1005, Lobbied to ensure safety of prescription drugs. H.R.700, Pharmaceutical Market Access Act of 1005, Lobbied to ensure safety of prescription drugs. H.R.898, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. H.R. 4550, The National Hepatitis B Awareness Act, Lobbied to raise awareness about Hepatitis B and for passage of the bill. H.R. 3559, Medicare DME Access Act, Lobbied to remove certain DME services from competitive bidding, implement quality standards, and passage of the bill. S.1064, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. WIC (no bill), Lobbied for improved nutrition and funding sources for the Supplemental Feeding Program for Women, Infants, and Children.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2005 · year_end · YY
H.R.2795, Patent Act of 2005, Lobbied to ensure strong IP protections for prescriptions drugs.
H.R.376, Medicare's Equitable Drugs for Seniors Act of 2005, Lobbied against signing a discharge petition to bring this bill to a floor vote. H.R.563, Prescription Drug Affordability Act of 2005, Lobbied to prevent passage of the bill. Lobbied to remove federally imposed cap on Puerto Rico for Medicaid funding.
Source: Senate LDA
Stroke Treatment and Ongoing Prevention Act of 2005
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.Con.Res.130, Expressing the sense of the Congress with respect to the awareness, prevention, early detection, and effective treatment of viral hepatitis, and for other purposes. Lobbied for awareness of Hepatitis B. H.R.2090, Food and Drug Administration Improvement Act of 2005. Lobbied to prevent provisions adverse to prescription drug approval process. H.R.3010, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2006, Lobbied for increased funding for AIDS Drug Assistance Program. H.R.328, Pharmaceutical Market Access Act of 1005, Lobbied to ensure safety of prescription drugs. H.R.700, Pharmaceutical Market Access Act of 1005, Lobbied to ensure safety of prescription drugs. H.R.898, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. H.R. 4550, The National Hepatitis B Awareness Act, Lobbied to raise awareness about Hepatitis B and for passage of the bill. H.R. 3559, Medicare DME Access Act, Lobbied to remove certain DME services from competitive bidding, implement quality standards, and passage of the bill. S.1064, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. WIC (no bill), Lobbied for improved nutrition and funding sources for the Supplemental Feeding Program for Women, Infants, and Children.
Dominican Republic-Central America-United States Free Trade Agreement Implementation Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
S.1307, Central American Free Trade Agreement, Lobbied for equitable treatment of pharmaceutical products. H.R. 3045, Central American Free Trade Agreement, Lobbied for equitable treatment of pharmaceutical products.
Tax Technical Corrections Act of 2005
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1736, Investment in America Act of 2005, Lobbied to extend the research and development tax credit. H.R.3, Transportation Equity Act, Lobbied to prevent enactment of unnecessary new taxes. H.R.809, To make permanent the individual income tax rates for capital gains and dividends, Lobbied to ensure passage. S.627, Investment in America Act of 2005, Lobbied to extend the research and development tax credit. S.7, Jobs and Growth Tax Relief Act of 2005, Lobbied to ensure passage and extend charitable contribution deduction to Sec. 965 repatriated funds. S.2020 Tax Relief Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. H.R.4297 Tax Relief Extension Reconciliation Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. H.R. 3376, Tax Technical Corrections Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. S.1447, Tax Technical Corrections Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions.
Affordable Health Care Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.2090, Food and Drug Administration Improvement Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. H.R.753, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. H.R.870, Pharmaceutical Research and Manufacturers Accountability Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.16, Affordable Health Care Act, Lobbied to prevent provisions adverse to prescription drug approval process. S.930, Food and Drug Administration Safety Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.184, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. S.470, FACT Act, Fair Access to Clinical Trials Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process.
Safe IMPORT Act of 2005
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.2090, Food and Drug Administration Improvement Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. H.R.753, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. H.R.870, Pharmaceutical Research and Manufacturers Accountability Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.16, Affordable Health Care Act, Lobbied to prevent provisions adverse to prescription drug approval process. S.930, Food and Drug Administration Safety Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.184, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. S.470, FACT Act, Fair Access to Clinical Trials Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process.
H.R.2090, Food and Drug Administration Improvement Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. H.R.753, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. H.R.870, Pharmaceutical Research and Manufacturers Accountability Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.16, Affordable Health Care Act, Lobbied to prevent provisions adverse to prescription drug approval process. S.930, Food and Drug Administration Safety Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.184, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. S.470, FACT Act, Fair Access to Clinical Trials Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process.
Investment in America Act of 2005
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1736, Investment in America Act of 2005, Lobbied to extend the research and development tax credit. H.R.3, Transportation Equity Act, Lobbied to prevent enactment of unnecessary new taxes. H.R.809, To make permanent the individual income tax rates for capital gains and dividends, Lobbied to ensure passage. S.627, Investment in America Act of 2005, Lobbied to extend the research and development tax credit. S.7, Jobs and Growth Tax Relief Act of 2005, Lobbied to ensure passage and extend charitable contribution deduction to Sec. 965 repatriated funds. S.2020 Tax Relief Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. H.R.4297 Tax Relief Extension Reconciliation Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. H.R. 3376, Tax Technical Corrections Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. S.1447, Tax Technical Corrections Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions.
Jobs and Growth Tax Relief Act of 2005
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1736, Investment in America Act of 2005, Lobbied to extend the research and development tax credit. H.R.3, Transportation Equity Act, Lobbied to prevent enactment of unnecessary new taxes. H.R.809, To make permanent the individual income tax rates for capital gains and dividends, Lobbied to ensure passage. S.627, Investment in America Act of 2005, Lobbied to extend the research and development tax credit. S.7, Jobs and Growth Tax Relief Act of 2005, Lobbied to ensure passage and extend charitable contribution deduction to Sec. 965 repatriated funds. S.2020 Tax Relief Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. H.R.4297 Tax Relief Extension Reconciliation Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. H.R. 3376, Tax Technical Corrections Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. S.1447, Tax Technical Corrections Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions.
Food and Drug Administration Safety Act of 2005
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.2090, Food and Drug Administration Improvement Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. H.R.753, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. H.R.870, Pharmaceutical Research and Manufacturers Accountability Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.16, Affordable Health Care Act, Lobbied to prevent provisions adverse to prescription drug approval process. S.930, Food and Drug Administration Safety Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.184, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. S.470, FACT Act, Fair Access to Clinical Trials Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process.
Supporting a National Charter Schools Week.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.Con.Res.95, Establishing the congressional budget for the United States Government for fiscal year 2006, revising appropriate budgetary levels for fiscal year 2005, and setting forth appropriate budgetary levels for fiscal year 2007 through 2010. Lobbied against an amendment to remove language from the MMA prohibiting HHS from interfacing in negotiations for the drug benefit. H.R.2744, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2006. Lobbied to ensure safety of prescription drugs. H.R.3010, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act 2006. Lobbied for increased funding for Ryan White program.
Economic Growth and Tax Relief Act of 2001
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1736, Investment in America Act of 2005, Lobbied to extend the research and development tax credit. H.R.3, Transportation Equity Act, Lobbied to prevent enactment of unnecessary new taxes. H.R.809, To make permanent the individual income tax rates for capital gains and dividends, Lobbied to ensure passage. S.627, Investment in America Act of 2005, Lobbied to extend the research and development tax credit. S.7, Jobs and Growth Tax Relief Act of 2005, Lobbied to ensure passage and extend charitable contribution deduction to Sec. 965 repatriated funds. S.2020 Tax Relief Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. H.R.4297 Tax Relief Extension Reconciliation Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. H.R. 3376, Tax Technical Corrections Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. S.1447, Tax Technical Corrections Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions.
S.1307, Central American Free Trade Agreement, Lobbied for equitable treatment of pharmaceutical products. H.R. 3045, Central American Free Trade Agreement, Lobbied for equitable treatment of pharmaceutical products.
H.Con.Res.130, Expressing the sense of the Congress with respect to the awareness, prevention, early detection, and effective treatment of viral hepatitis, and for other purposes. Lobbied for awareness of Hepatitis B. H.R.2090, Food and Drug Administration Improvement Act of 2005. Lobbied to prevent provisions adverse to prescription drug approval process. H.R.3010, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2006, Lobbied for increased funding for AIDS Drug Assistance Program. H.R.328, Pharmaceutical Market Access Act of 1005, Lobbied to ensure safety of prescription drugs. H.R.700, Pharmaceutical Market Access Act of 1005, Lobbied to ensure safety of prescription drugs. H.R.898, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. H.R. 4550, The National Hepatitis B Awareness Act, Lobbied to raise awareness about Hepatitis B and for passage of the bill. H.R. 3559, Medicare DME Access Act, Lobbied to remove certain DME services from competitive bidding, implement quality standards, and passage of the bill. S.1064, Stroke Treatment and Ongoing Prevention Act, Lobbied for passage of the bill. WIC (no bill), Lobbied for improved nutrition and funding sources for the Supplemental Feeding Program for Women, Infants, and Children.
H.Con.Res.95, Establishing the congressional budget for the United States Government for fiscal year 2006, revising appropriate budgetary levels for fiscal year 2005, and setting forth appropriate budgetary levels for fiscal year 2007 through 2010. Lobbied against an amendment to remove language from the MMA prohibiting HHS from interfacing in negotiations for the drug benefit. H.R.2744, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2006. Lobbied to ensure safety of prescription drugs. H.R.3010, Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act 2006. Lobbied for increased funding for Ryan White program.
H.R.2090, Food and Drug Administration Improvement Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. H.R.753, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. H.R.870, Pharmaceutical Research and Manufacturers Accountability Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.16, Affordable Health Care Act, Lobbied to prevent provisions adverse to prescription drug approval process. S.930, Food and Drug Administration Safety Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process. S.184, Safe IMPORT Act of 2005, Lobbied to prevent unsafe importation of prescription drugs. S.470, FACT Act, Fair Access to Clinical Trials Act of 2005, Lobbied to prevent provisions adverse to prescription drug approval process.
H.R.1736, Investment in America Act of 2005, Lobbied to extend the research and development tax credit. H.R.3, Transportation Equity Act, Lobbied to prevent enactment of unnecessary new taxes. H.R.809, To make permanent the individual income tax rates for capital gains and dividends, Lobbied to ensure passage. S.627, Investment in America Act of 2005, Lobbied to extend the research and development tax credit. S.7, Jobs and Growth Tax Relief Act of 2005, Lobbied to ensure passage and extend charitable contribution deduction to Sec. 965 repatriated funds. S.2020 Tax Relief Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. H.R.4297 Tax Relief Extension Reconciliation Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. H.R. 3376, Tax Technical Corrections Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions. S.1447, Tax Technical Corrections Act of 2005, Lobbied to amend the IRS Section 170 definition of income for purposes of charitable deductions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2005 · mid_year · MM
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2004 · mid_year · MM
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2003 · year_end · YY
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2003 · mid_year · MM
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2003 · mid_year · RA
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2002 · year_end · YY
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)